Skip to main content
2024 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Chukwunonso K. Nwabufo, M.S, M.B.A., PhD (c)

PhD Candidate and CIHR Scholar
University of Toronto
Toronto, Ontario, Canada

Chukwunonso Nwabufo is a PhD Candidate and CIHR Scholar in pharmaceutical sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto, Canada. He is a multiple award-winning clinical pharmacologist with over six years of experience in drug development across academia and the pharmaceutical industry. Nwabufo contributed to the development of Remdesivir and Lenacapavir approved for the treatment of COVID-19 and HIV respectively, during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease during his MSc program.

Nwabufo’s current research work is focused on deploying pharmacological strategies to improve the clinical efficacy and safety profile of promising COVID-19 drugs. His research work has received the prestigious Canadian Institutes of Health Research Award ($110,000), and $121,000 in funding from the Leslie Dan Faculty of Pharmacy.

Nwabufo has received more than 20 international and national awards and recognitions worth more than C$400,000 in funding including the Emerging Academic Scholars Award, and Top 25 Canadian Immigrant Award due to academic, research, and leadership accomplishments. Nwabufo is the author of 17 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs.

Disclosure information not submitted.

Presentation(s):